CD8A and cytomegalovirus infection: To model this clinical need, a first application of the here newly described HLA-A2.1 transgenic mouse CMV infection model was to test the in vivo antiviral function of human CD8 as well as CD4 T cells that were transduced by retroviral gene transfer of a modified high-affinity human T-cell receptor α/β (TCRNLV) previously shown to reprogram CD8 and CD4 T cells derived from HCMV-seronegative donors [16].